[A22-119] Pembrolizumab (breast cancer) - Addendum to Commission A22-63
Last updated 15.12.2022
Commission awarded on 08.11.2022 by the Federal Joint Committee (G-BA).
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A22-63||Pembrolizumab (breast cancer) - Benefit assessment according to § 35a Social Code Book V||Commission completed|
Federal Joint Committee (G-BA)
2022-12-15 A G-BA decision was published.
G-BA documents on this decision